Skip to main content
BIOVIE INC. logo

BIOVIE INC. — Investor Relations & Filings

Ticker · BIVI ISIN · US09074F4054 US Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2017-01-19 Regulatory Filings
Country US United States of America
Listing US BIVI

About BIOVIE INC.

https://www.bioviepharma.com/

BioVie Inc. is a clinical-stage biopharmaceutical company that develops drug therapies for chronic debilitating conditions. The company's pipeline focuses on neurological and neurodegenerative disorders as well as advanced liver disease. Its lead drug candidate, bezisterim, is being studied for Alzheimer's disease based on the hypothesis that modulating inflammation and enhancing insulin sensitivity in the brain can improve cognitive function and provide neuroprotection. Other areas of focus include Parkinson's disease, ascites (a common complication of advanced liver cirrhosis), and Long COVID. The company also conducts research into epigenetic mechanisms, such as DNA methylation, to understand gene expression regulation.

Recent filings

Filing Released Lang Actions
FORM S-1
Regulatory Filings Classification · 95% confidence The document is a Form S-1 Registration Statement filed with the SEC, dated January 19, 2017, for BioVie Inc. It is a registration statement under the Securities Act of 1933, used for initial public offerings or other securities offerings. The text includes details about the offering, selling stockholder, risk factors, management discussion, and financial statements index. This is not an annual report, earnings release, or other financial report but a registration statement for securities offering. The appropriate classification for this type of document is Regulatory Filings (RNS), as it is a regulatory filing that does not fit into other specific categories like capital/financing update or proxy solicitation. The document is lengthy (15,000 characters) and contains substantive information about the offering, but it is not a financial report or presentation per se.
2017-01-19 English
AMENDMENT NO.1 TO FORM 10-Q
Interim / Quarterly Report Q1 2017
2017-01-19 English
Regulatory Filings 2017
Regulatory Filings
2017-01-19 English
CURRENT REPORT
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated January 4, 2017, by BioVie Inc. It details the entry into a material definitive agreement, specifically a common stock purchase agreement and registration rights agreement with Aspire Capital Fund, LLC. The content focuses on the terms of the financing agreement, including stock purchase commitments, warrants, and registration rights. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document is an update on a capital raising transaction and financing activity. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (over 10,000 characters), and it is not merely an announcement or a certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA).
2017-01-05 English
CURRENT REPORT
Board/Management Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated December 27, 2016. It reports the election of a new director to the Board of Directors and an update on the FDA's hold on a clinical study. The content focuses on management changes and regulatory updates rather than financial results or detailed financial statements. The document length is 3296 characters, which is relatively short and primarily contains announcements rather than comprehensive reports. The key section is Item 5.02(d) Election of Directors, indicating a change in the board. Therefore, the document fits best under Board/Management Information (MANG).
2016-12-27 English
Interim / Quarterly Report 2017
Interim / Quarterly Report Q1 2017
2016-11-16 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.